annb0t
Top 20
Key Insights
Using the 2 Stage Free Cash Flow to Equity, ResMed fair value estimate is US$338 ResMed is estimated to be 31% undervalued based on current share price of US$234 The US$256 analyst price target for RMD is 24% less than our estimate of fair value
In this article we are going to estimate the intrinsic value of ResMed Inc. (NYSE:RMD) by projecting its future cash flows and then discounting them to today's value. The Discounted Cash Flow (DCF) model is the tool we will apply to do thi...
>>> Read more: Is There An Opportunity With ResMed Inc.'s (NYSE:RMD) 31% Undervaluation?
Using the 2 Stage Free Cash Flow to Equity, ResMed fair value estimate is US$338 ResMed is estimated to be 31% undervalued based on current share price of US$234 The US$256 analyst price target for RMD is 24% less than our estimate of fair value
In this article we are going to estimate the intrinsic value of ResMed Inc. (NYSE:RMD) by projecting its future cash flows and then discounting them to today's value. The Discounted Cash Flow (DCF) model is the tool we will apply to do thi...
>>> Read more: Is There An Opportunity With ResMed Inc.'s (NYSE:RMD) 31% Undervaluation?
